|

68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma

RECRUITINGPhase 1/2Sponsored by Peking Union Medical College Hospital
Actively Recruiting
PhasePhase 1/2
SponsorPeking Union Medical College Hospital
Started2026-06-11
Est. completion2027-04-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This is a prospective, single-center, single-arm, phase I/II study designed to evaluate (1) the safety, tolerability, and imaging characteristics of 68Ga-NYM207 (Phase A), and (2) the diagnostic performance of 68Ga-NYM207 in detecting hepatocellular carcinoma (HCC) (Phase B). This study will provide critical insights into the performance of 68Ga-NYM207 PET/CT as a non-invasive imaging tool for the detection of HCC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. ≥18 years of age and of either gender;
2. Written informed consent provided for participation in the trial;
3. At least one of the following indications should be applied:

   1. scheduled for surgical resection or biopsy of the liver mass suspected of HCC within one month;
   2. with a history of HCC, recurrence or metastasis during follow-up (based on laboratory examination or typical appearance of imaging data including conventional imaging or 18F-FDG PET/CT scan);
4. Willing and able to follow schedule visits, treatment plans and laboratory tests.

Exclusion Criteria:

1. Pregnancy or lactation;
2. Severe claustrophobia;
3. On treatment with anti-tumor drugs targeting GPC3;
4. Any condition deemed by the investigator to interfere with study results or increase participant risk.

Conditions4

CancerHepatocellular Carcinoma (HCC)Liver CancerLiver Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.